These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 10817741

  • 1. Efficacy of FK463, a (1,3)-beta-D-glucan synthase inhibitor, in disseminated azole-resistant candida albicans infection in mice.
    Maesaki S, Hossain MA, Miyazaki Y, Tomono K, Tashiro T, Kohno S.
    Antimicrob Agents Chemother; 2000 Jun; 44(6):1728-30. PubMed ID: 10817741
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis.
    Ikeda F, Wakai Y, Matsumoto S, Maki K, Watabe E, Tawara S, Goto T, Watanabe Y, Matsumoto F, Kuwahara S.
    Antimicrob Agents Chemother; 2000 Mar; 44(3):614-8. PubMed ID: 10681327
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi.
    Tawara S, Ikeda F, Maki K, Morishita Y, Otomo K, Teratani N, Goto T, Tomishima M, Ohki H, Yamada A, Kawabata K, Takasugi H, Sakane K, Tanaka H, Matsumoto F, Kuwahara S.
    Antimicrob Agents Chemother; 2000 Jan; 44(1):57-62. PubMed ID: 10602723
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [The future of antifungal agents. Non azole antifungal agents].
    Maesaki S, Hossain MA, Sasaki E, Hashiguchi K, Higashiyama Y, Yoshitsugu Y, Tomono K, Tashiro T, Kohno S.
    Nihon Ishinkin Gakkai Zasshi; 1999 Jan; 40(3):157-61. PubMed ID: 10423510
    [Abstract] [Full Text] [Related]

  • 7. [Antifungal activity and clinical efficacy of micafungin sodium (Funguard)].
    Ikeda F.
    Nihon Yakurigaku Zasshi; 2003 Oct; 122(4):339-44. PubMed ID: 14501170
    [Abstract] [Full Text] [Related]

  • 8. In vitro antifungal activity of FK463, a new water-soluble echinocandin-like lipopeptide.
    Mikamo H, Sato Y, Tamaya T.
    J Antimicrob Chemother; 2000 Sep; 46(3):485-7. PubMed ID: 10980180
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Activity of micafungin (FK463) against an itraconazole-resistant strain of Aspergillus fumigatus and a strain of Aspergillus terreus demonstrating in vivo resistance to amphotericin B.
    Warn PA, Morrissey G, Morrissey J, Denning DW.
    J Antimicrob Chemother; 2003 Apr; 51(4):913-9. PubMed ID: 12654746
    [Abstract] [Full Text] [Related]

  • 11. The echinocandin micafungin: a review of the pharmacology, spectrum of activity, clinical efficacy and safety.
    Wiederhold NP, Lewis JS.
    Expert Opin Pharmacother; 2007 Jun; 8(8):1155-66. PubMed ID: 17516879
    [Abstract] [Full Text] [Related]

  • 12. Micafungin: a therapeutic review.
    Higashiyama Y, Kohno S.
    Expert Rev Anti Infect Ther; 2004 Jun; 2(3):345-55. PubMed ID: 15482200
    [Abstract] [Full Text] [Related]

  • 13. Effect of neutropenia and treatment delay on the response to antifungal agents in experimental disseminated candidiasis.
    Hope WW, Drusano GL, Moore CB, Sharp A, Louie A, Walsh TJ, Denning DW, Warn PA.
    Antimicrob Agents Chemother; 2007 Jan; 51(1):285-95. PubMed ID: 17088486
    [Abstract] [Full Text] [Related]

  • 14. Acquired resistance to echinocandins in Candida albicans: case report and review.
    Baixench MT, Aoun N, Desnos-Ollivier M, Garcia-Hermoso D, Bretagne S, Ramires S, Piketty C, Dannaoui E.
    J Antimicrob Chemother; 2007 Jun; 59(6):1076-83. PubMed ID: 17468115
    [Abstract] [Full Text] [Related]

  • 15. [Antifungal activity and clinical efficacy of micafungin (funguard)].
    Ikeda F.
    Nihon Ishinkin Gakkai Zasshi; 2005 Jun; 46(4):217-22. PubMed ID: 16282962
    [Abstract] [Full Text] [Related]

  • 16. The efficiency of the benzothiazole APB, the echinocandin micafungin, and amphotericin B in fluconazole-resistant Candida albicans and Candida dubliniensis.
    Melkusová S, Bujdáková H, Volleková A, Myoken Y, Mikami Y.
    Pharmazie; 2004 Jul; 59(7):573-4. PubMed ID: 15296100
    [Abstract] [Full Text] [Related]

  • 17. Synergic effects of tactolimus and azole antifungal agents against azole-resistant Candida albican strains.
    Maesaki S, Marichal P, Hossain MA, Sanglard D, Vanden Bossche H, Kohno S.
    J Antimicrob Chemother; 1998 Dec; 42(6):747-53. PubMed ID: 10052898
    [Abstract] [Full Text] [Related]

  • 18. Micafungin: a new echinocandin.
    Chandrasekar PH, Sobel JD.
    Clin Infect Dis; 2006 Apr 15; 42(8):1171-8. PubMed ID: 16575738
    [Abstract] [Full Text] [Related]

  • 19. Micafungin activity against Candida albicans with diverse azole resistance phenotypes.
    Richards TS, Oliver BG, White TC.
    J Antimicrob Chemother; 2008 Aug 15; 62(2):349-55. PubMed ID: 18436555
    [Abstract] [Full Text] [Related]

  • 20. In vivo activity of micafungin in a persistently neutropenic murine model of disseminated infection caused by Candida tropicalis.
    Warn PA, Sharp A, Morrissey G, Denning DW.
    J Antimicrob Chemother; 2002 Dec 15; 50(6):1071-4. PubMed ID: 12461036
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.